<DOC>
	<DOC>NCT00329303</DOC>
	<brief_summary>The primary objective is to assess the effect of re-treatment after relapse in subjects with moderate to severe chronic plaque psoriasis having responded to a first treatment.</brief_summary>
	<brief_title>Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subject having responded to treatment in study C87040 and having relapsed during the followup period. Erythrodermic, guttate, palmar or plantar, generalized pustular form of psoriasis; A history of chronic infection, recent serious or lifethreatening infection (within six months, including herpes zoster), or any current sign or symptom that may indicate an infection (e.g. fever, cough); White blood cell counts less than 4000/mm3 or more than 20000/mm3; Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis); Systemic Lupus; Non respect of adequate wash out periods for treatments that might have an impact on the disease Any associated disease that could be impacted by the study treatment intake Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Moderate to severe chronic plaque psoriasis</keyword>
	<keyword>anti TNF α</keyword>
	<keyword>CDP 870</keyword>
	<keyword>Cimzia®</keyword>
	<keyword>certolizumab pegol</keyword>
	<keyword>retreatment</keyword>
</DOC>